Alzheimer's disease versus vascular dementia - Dichotomy or interaction?;Alzheimer demenz versus vaskuläre demenz - Dichotomie oder interaktion?

Fortschritte der Neurologie Psychiatrie

Volumn 73, Issue 6, 2005, Pages 317-326

  Hentschel, F ^a   Supprian, T ^b   Frolich L ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b Klinik für Psychiatrie und Psychotherapie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DISEASE COURSE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; HUMAN; HYALINE DEGENERATION; MICROANGIOPATHY; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; PHENOMENOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; BRAIN; DEMENTIA, VASCULAR; HUMANS;

EID: 21244450796     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830101     Document Type: Article

References (117)

1. MacKhann G, Drachmann D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of departement of health and human service task force on Alzheimer's disease. Neurology 1984; 34: 939-944
2. Roman GC, Tatemichi TK, Erkinjuntti T et mult al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260
3. Zekry D, Duyckaerts C, Belmin J et al. Alzheimer's disease and brain infarcts in the elderly. Agreement with neuropathology. J Neurol 2002; 249: 1529-1534
4. Hentschel F, Damian M, Kreis M, Krumm B. Auswirkungen der erweiterten klinischen Diagnostik auf das Diagnosespektrum einer Gedächtnisambulanz. Gerontologie und Geriatrie 2004; 37: 145-154
5. Bigler ED, Kerr B, Victoroff J et al. White matter lesions, quantitative magnetic resonance imaging, and dementia. Alzheimer Dis Assoc Disord 2002; 16: 161-170
6. Wallin A. The overlap between Alzheimer's disease and vascular dementia: The role of white matter changes. Dement Geriat Cogn Disord 1998; 9: 30-35
7. Hentschel F, Kölsch H, Heun R. Molekulargenetische Untersuchungen bei Patienten mit klinisch diagnostizierter subkortikaler vaskulärer Demenz. DFG-Antrag, 2003
8. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981
9. Panza F, D'Introno A, Colacicco AM et al. Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm 2004; 111: 69-89
10. Huang HM, Kuo YM, On HCl. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. J Neural Transm 2002; 109: 1415-1421
11. McIlroy SP, Dynan KB, Lawson JT. Moderately elevated plasma homocystein, methylenetetrahydrofolate reductasegenotype, and risk for stroke, vaskular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33: 2351
12. Bronge L, Fernaeus SE, Blomberg M et al. White matter lesions in Alzheimer patients are influenced by Apolipoprotein E genotype. Dement Geriat Cogn Disord 1999; 10: 89-96
13. Leys D, Pasquir F, Parnetti L. Epidemiology of vascular dementia. Haemostasis 1998; 28: 134-150
14. Frank A, Díez-Tejedor E, Bullido MJ et al. ApoE genotype in cerebrovascular disease and vascular dementia. J Neurol Sci 2002; 203-204: 173-176
15. Traykov L, Rigaud AS, Baudic S et al. Apolipoprotein ε 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease. J Neurol Sci 2002; 203-204: 177-181
16. Söderberg M, Edlund C, Kristensson K. Lipid composition of different regions of the human brain during aging. J Neurochem 1990; 54: 415-423
17. Svennerholm L, Boström K, Helander CG et al. Membrane lipids in the aging human brain. J Neurochem 1991; 56: 2051-2059
18. Svennerholm L, Boström K, Jungbjer B et al. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem 1994; 63: 1.802-1.811
19. Söderberg M, Edlung C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26: 412-425
20. Zhang Y, Appelkvist EL, Kristensson K et al. The lipid composition of different regions of rat brain during development and aging. Neurobiol Aging 1996; 17: 869-875
21. Mason RP, Shoemaker WJ, Shajenko L et al. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 1992; 13: 413-419
22. Terracina L, Brunetti M, Avellini L et al. Arachidonic and palmatic acid utilization in aged rat brain areas. Mol Cell Biochem 1992; 115: 35-42
23. Igbavboa U, Avdulow A, Schröder F, Wood WG. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem 1996; 66: 1717-1725
24. Cullis PR, Hope MJ. Physical properties und functional roles of lipids in membranes. In: Vance DE, Vance J (eds.). Biochemistry of lipids, lipoproteins and membranes. Elsevier, Amsterdam, New York, 1991: 1-40
25. Vedie B, Jeunemaitre X, Megnien JL et al. A new DNA polymorphism in the 5′ untranslated region of the human SREBP-1a is related to development of atherosclerosis in high cardiovascular risk population. Atherosclerosis 2001; 154: 589-597
26. Klein J. Membrane breakdown in acute and chronic neurodegeneration. Focus on choline containing phospholipids. J Neural Transm 2000; 107: 1027-1063
27. Mulder M, Ravid R, Swaab DF et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebral spinal fluid of Alzheimer disease patients are not related to apolipoprotein E 4. Alzheimer Dis Ass Disord 1998; 12: 198-203
28. Lütjohann D, Breuer O, Ahlborg G et al. Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 1996; 93: 9799-804
29. Mori E, Ishii K, Hashimoto M et al. Role of functional brain imaging in the evaluation of vascular dementia. Alzheimer Disease and Associated Disorders 1999; 13: S91-S101
30. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimers disease. Neurobiol Aging 2003; 25: 5-18
31. Braak H, DelTredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2003; 25: 19-23
32. Kojro E, Gimpl G, Lammich S et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM. Proc Natl Acad Sci USA 2002; 98: 5815-5820
33. Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861
34. Wolozin B, Kellman W, Ruosseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase in-hibitors. Arch Neurol 2000; 57: 1439-1443
35. Simons K, Ikonen E. How cells handle cholesterol. Science 2000; 290: 1721-1726
36. Papassotiropoulos A, Lütjohann D, Bagli M et al. 24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 2002; 36: 27-32
37. Panzenboeck U, Balazs Z, Sovic A et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem 2002; 277: 42781-42789
38. Hatanaka Y, Kamino K, Fukuo K et al. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population. Clin Genet 2000; 58: 319-323
39. Kang DE, Pietrzik CU, Baum L et al. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106: 1159-1166
40. Erecinska M, Silver IA. ATP and brain function. J Cereb Blood Flow Metab 1989; 9: 2-19
41. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 1995; 312: 163-167
42. Davies RE, Miller S, Herrnstadt C et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 4526-4531
43. Dyrks T, Dyrks E, Hartmann T et al. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metalcatalyzed oxidation. J Biol Chem 1992; 67: 18210-18217
44. Gabuzda D, Busciglio J, Chen LB et al. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 1994; 269: 13623-13628
45. Frölich L, Blum-Degen D, Bernstein HG et al. Insulin and insulin receptors in the brain in aging and in sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-438
46. Frölich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance of the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 1999; 893: 290-294
47. Gasparini L, Gouvas GK, Wang R et al. Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneural β-amyloid and requires nitrogen-activated protein kinase signalicy. J Neurosci 2000; 21: 2561-2570
48. Evans D, Aberle J, Wendt D et al. A polymorphism, L162V, in the peroxisome proliferator-activated receptor α (PPARα) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 2001; 79: 198-204
49. Hara M, Wang X, Paz VP et al. Identification of three missense mutations in the peroxisome proliferator-activated receptor alpha gene in Japanese subjects with maturity-onset diabetes of the young. J Hum Genet 2001; 46: 285-288
50. Flavell DM, Jamshidi Y, Hawe E et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105; 1440-1445
51. Combs CK, Johnson DE, Karlo JC et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000; 20: 558-567
52. Schmidt R, Schmidt H, Curb JD et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-174
53. Grimaldi LME, Casadei VM, Ferri C et al. Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism. Ann Neurol 2000; 47: 361-368
54. Kölsch H, Ptok U, Bagli M et al. Gene polymorphisms of interleukin-1α influence the course of Alzheimer's disease. Ann Neurol 2001; 49: 818-819
55. Rogers J. An IL-1α susceptibility polymorphism in Alzheimer's disease. Neurology 2000; 55: 464-465
56. Zaremba J, Losy J. sPECAM-1 in serum and CSF of acute ischaemic stroke patients. Acta Neurol Scand 2002; 106: 292-298
57. Cheng CY, Hong CJ, Liu HC et al. Study of the association between Alzheimer's disease and angiotensin-converting enzyme gene polymorphism using DNA from lymphocytes. Eur Neurol 2002; 47: 26-29
58. Myllykangas L, Polvikoski T, Sulkava R et al. Cardiovascular risk factors and Alzheimer's disease: a genetic association study in a population aged 85 or over. Neurosci Lett 2000; 292: 195-198
59. Losito A, Kalidas K, Santoni S et al. Polymorphism of renin-angiotensin system genes in dialysis patients-association with cerebrovascular disease. Nephrol Dial Transplant 2002; 17: 2184-2188
60. Vasku A, Soucek M, Tschoplova S, Stejskalova A. An association of BMI with A (-6) G, M235T and T174M polymorphisms in angiotensinogen gene in essential hypertension. J Hum Hypertens 2002; 16: 427-430
61. Szolnoki Z, Somogyvari F, Kondacs A et al. Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischemic stroke. J Neurol Neurosurg Psychiatry 2003; 74; 1615-1620
62. Reif A, Schneider MF, Kamolz S, Pfuhlmann B. Homocysteinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients. J Neural Transm 2003; 110: 1401-1411
63. Kessler H, Bleich S, Falkai P, Supprian T. Homozystein und Demenzer-krankungen. Fortschr Neurol Psychiat 2003; 71: 150-156
64. Kim NK, Choi BO. Jung WS et al. Hyperhomocysteinemia as an independent risk factor for silent brain infarction. J Neurol 2003; 61: 1595-1599
65. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34: 335-337
66. Honig LS, Tang MX, Albert S et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003; 60: 1707-1712
67. Ball MJ. White matter lesions, dementia, and ischemiv axonopathy (letter). Alzheimer Dis Assoc Disord 2003; 17: 55
68. Jellinger K, Attems J. Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study. Acta Neuropathol 2003; 105: 14-17
69. Hentschel F, Kreis M, Damian M, Krumm B. Mikroangiopathische Läsionen in der weißen Hirnsubstanz: Quantifizierung und Korrelation mit psychologischen Testergebnissen. Nervenarzt 2003; 74: 55-61
70. Snowdon DA, Greiner LH, Mortimer JA. Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997; 277: 813-817
71. Mungas D, Reed BR, Ellis WG, Jagust WJ. The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Archiv of Neurology 2001; 58: 1243-1247
72. Crystal H, Dickson D. Cerebral infarcts in patients with autopsy proven Alzheimer's disease (abstract). Neurobiol Aging 2002; 23 (Suppl1):207
73. Jernigan TL, Fennema-Notestine C. White matter mapping is needed. Neurobiol Aging 2003; 25: 37-39
74. Wardlaw JM. Sandercock PAG, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leucoaraiosis, and dementia? Stroke 2003; 34: 806-812
75. Corey-Bloom J, Thal LJ, Galasko D et al. Diagnosis and evaluation of dementia. J Neurol 1995; 45: 211-218
76. Hentschel F, Kreis M, Damian M et al. Evaluation des Beitrages der radiologischen bildgebenden Diagnostik bei demenziellen Erkrankungen - ein Vergleich mit der psychologischen Diagnostik. Fortschr Röntgenstr 2003b; 175: 1335-1343
77. Fazekas F, Schmidt R, Scheltens P. Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dementia 1988; 9 (Suppl 1): 2-5
78. Hirono N, Yasuda M, Tanimukai S et al. Effects of the Apolipoprotein E4 allele on white matter hyperintensities in dementia. Stroke 2000; 31: 1263-1268
79. Bronge L, Wahlund LO. Prognostic significance of white matter changes in a memory clinic population. Psych Res Neuroimaging 2003; 122: 199-206
80. Schmidt R, Roob G, Kapeller P et al. Longitudinal changes of white matter abnormalities. Neurobiol Ageing 2000; 21: 19-26
81. Scheltens P, Barkhof F, Valk J et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Brain 1992; 115: 735-74S
82. Schmidtke K, Hüll M. Neuropsychological differentiation of small vessel disease. Alzheimer's disease and mixed dementia. J Neurol Sci 2002; 203-204: 17-22
83. Barber R, Scheltens P, Gholkar A et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies. Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 2002; 67: 66-72
84. Wallin A, Sjögren M, Edman A et al. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol 2002; 44: 229-235
85. Margrave R, Geck LC, Reed B, Mungas D. Affective behavioural disturbances in Alzheimer's disease and ischemic vascular disease. J Neurol Neurosurg Psychiat 2000; 68: 41-46
86. Marti-Fabregas J, Valencia C, Lopez-Contreras J et al. Blood pressure variability in Biswanger's disease and isolated lacunar infarction. Cerebrovascular Diseases 2001; 11: 230-234
87. Honig LS, Tang MX, Albert S et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003; 60: 1707-1712
88. Schuff N, Capizzano AA, Du AT et al. Different pattern of N-acetylas-partate loss in subcortical ischemic vascular dementia and AD. J Neurol 2003; 61: 358-364
89. Burggren AC, Small GW, Sabb FW. Bookheimer SY. Specifity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 44-51
90. DeCarli C, Grady CL, Clark CM et al. Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter. J Neurol Neurosurg Psychiatry 1996; 60: 158-167
91. Tohgi H, Yonezawa H, Takahashi S et al. Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes. Neuroradiology 1998; 40: 131-137
92. Damian M, Kreis M, Krumm B et al. Diskriminante Validität neuropsychologischer Verfahren in der Demenzdiagnostik. Z Neuropsychol 2003; 14: 271-282
93. Looi JCL, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53: 670-678
94. Cannata AP, Alberoni M, Franceschi M, Mariani C. Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer's disease. Dement Geriat Cogn Disord 2002; 13: 101-111
95. Snowden JS. Neuropsychological evaluation and the diagnosis and differentialdiagnosis of dementia. Reviews in Clinical Gerontology 1999; 9: 65-75
96. Pasquir F. Early diagnosis of dementia: neuropsychology. Neurology 1999; 246: 6-15
97. Damian M, Kreis M, Krumm B, Hentschel F. Optimized neuropsychological procedures for different levels of dementia diagnostics.: J Neurol Sci (in press)
98. Barr A, Benedict R, Tune L, Brandt J. Neuropsychological differentiation of Alzheimer's disease from vascular dementia. Int J Geriatr Psychiatry 1992; 7: 621-627
99. Kertesz A. Neuropsychological deficits in vascular dementia vs. Alzheimer's disease. Frontal lobe deficits prominent in vascular dementia. Arch Neurol 1994; 51: 1226-1231
100. Mendez MF, Chertier MM, Ferryman KM. Differences between Alzheimer's disease and vascular dementia on information processing measures. Brain and Cognition 1997; 34: 301-310
101. Oswald WD, Fleischmann UM. Das Nürnberger Altersinventar (NAI). Testzentrale Göttingen, 1995
102. Reitan RM, Wolfson D. Category test and trail making test as measures of frontal lobe functions. Clinical Neuropsychologist 1995; 0: 50-56
103. Villardita C. Alzheimer's disease compared with cerebrovascular dementia: neuropsychological similarities and differences. Acta Neurol Scand 1993; 87: 299-308
104. Reischies FM. Demenzen. In: Karnath HO, Their P (Hrsg.). Neuropsychologie. Heidelberg, Springer, 2003: 727-736
105. Bowler JV. The concept of vascular cognitive impairment. J Neurol Sci 2002; 203-204: 11-15
106. Amenta F, DiTullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-dinical and clinical studies. Clin Exp Hypertens 2002; 24: 697-713
107. Grantham C, Geerts H. The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci 2002; 203-204: 131-136
108. Erkinjuntti T, Kurz A, Gauthier S et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-1290
109. Frölich L, Klinger T, Berger FM. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. J Neurol Sci 2003; 203-204: 137-139
110. Moretti R, Torre P, Antonelle RM et al. Rivastigmine in subcortical vascular dementia: "an open 22-month study". J Neurol Sci 2002; 203-204: 141-146
111. Orgogozo JM, Rigaud AS, Stöffler A. Efficacy and safety of memantine in patients with mild to moderate vascular dementia. Stroke 2002; 33: 1834-1839
112. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297-305
113. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovascular Diseases 2002; 13 (Suppl 2): 11-15
114. Hachinski V. Vascular behavioral and cognitive disorders (Editorial). Stroke 2003; 34: 2775
115. DelaTorre JC. Alzheimer disease as a vascular disorder. Stroke 2002; 33: 1152-1162
116. Royall DR. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 2147
117. DeCarli C. The role of cerebrovascular disease in dementia. The Neurologist 2003; 9: 123-136